CoChat

Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin

Vanderheiden, Anna, Harrison, Lindsay B., Warshauer, Jeremy T., Adams-Huet, Beverley, Li, Xilong, Yuan, Qing, Hulsey, Keith, Dimitrov, Ivan, Yokoo, Takeshi, Jaster, Adam W., Pinho, Daniella F., Pedrosa, Ivan, Lenkinski, Robert E., Pop, Laurentiu M., Lingvay, Ildiko · 2016 · The Journal of Clinical Endocrinology & Metabolism
Cited by 76

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Context: The mechanisms of action of incretin mimetics in patients with long-standing type 2 diabetes (T2D) and high insulin requirements have not been studied. Objective: To evaluate changes in β-cell function, glucagon secretion, and fat distribution after addition of liraglutide to high-dose insulin. Design: A single-center, randomized, double-blind, placebo-controlled trial. Setting: University of Texas Southwestern and Parkland Memorial Hospital clinics. Patients: Seventy-one patients with long-standing (median, 17 years) T2D requiring high-dose insulin treatment (>1.5 U/kg/d; average, 2.2 ± 0.9 U/kg/d). Intervention: Patients were randomized to liraglutide 1.8 mg/d or matching placebo for 6 months. Main Outcome Measures: We measured changes in insulin and glucagon secretion using a 4-hour mixed-meal challenge test. Magnetic resonance-based techniques were used to estimate sc and visceral fat in the abdomen and ectopic fat in the liver and pancreas. Results: Glycosylated hemoglobin improved significantly with liraglutide treatment, with an end-of-trial estimated treatment difference between groups of −0.9% (95% confidence interval, −1.5, −0.4%) (P = .002). Insulin secretion improved in the liraglutide group vs placebo, as measured by the area under the curve of C-peptide (P = .002) and the area under the curves ratio of C-peptide to glucose (P = .003). Insulin sensitivity (Matsuda index) and glucagon secretion did not change significantly between groups. Liver fat and sc fat decreased in the liraglutide group vs placebo (P = .0006 and P = .01, respectively), whereas neither visceral nor pancreatic fat changed significantly. Conclusions: Treatment with liraglutide significantly improved insulin secretion, even in patients with long-standing T2D requiring high-dose insulin treatment. Liraglutide also decreased liver and sc fat, but it did not alter glucagon secretion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2015-3906

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 76

Metadata

Authors
Vanderheiden, A., Harrison, L. B., Warshauer, J. T., Adams-Huet, B., Li, X., Yuan, Q., Hulsey, K., Dimitrov, I., Yokoo, T., Jaster, A. W., Pinho, D. F., Pedrosa, I., Lenkinski, R. E., Pop, L. M., & Lingvay, I.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2016-04-01
Volume
101
Issue
4
Pages
1798-1806
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2273945206
Cited by
76
References
18
FWCI
2.60
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. https://app.cochat.ai/papers/10.1210/jc.2015-3906
The paper
Vanderheiden, A., Harrison, L. B., Warshauer, J. T., Adams-Huet, B., Li, X., Yuan, Q., Hulsey, K., Dimitrov, I., Yokoo, T., Jaster, A. W., Pinho, D. F., Pedrosa, I., Lenkinski, R. E., Pop, L. M., & Lingvay, I. (2016). Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2015-3906

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.